abstract | Lupus nephritis is a challenging clinical condition for which current therapies are unsatisfactory with respect to both remission induction and unwanted toxic effects. Despite intervention, the rates of end-stage renal disease seem to be increasing in the USA. Discoveries over the past decade have greatly improved our understanding of immune activation and effector inflammatory pathways in lupus nephritis; however, this increased understanding has not yet translated into the approval of an effective new therapeutic agent. An analysis of the mechanisms of action of novel immunomodulatory drugs in multiple models of murine lupus clearly shows that interacting networks of immune and effector pathways are recruited as the disease progresses. Reversing established disease by targeting a single cell population or inflammatory pathway is, therefore, difficult once long-lived autoreactive lymphocyte populations are present and peripheral organs are inflamed. Data from murine models of lupus suggest that we need to consider new paradigms for the management of systemic lupus erythematosus that include earlier immune intervention, long-term maintenance therapies and protection of target organs.
Introduction
nephritis is a challenging problem that affects 30-60% of patients with systemic lupus erythematosus (sle). 1, 2 outcomes after broad-spectrum immunosuppressive therapy remain unsatisfactory, with complete remission rates of 50% at best, 3 relapse rates of up to 30% over a 2-year period 4 and the occurrence of unacceptable toxic effects. 5 Despite the implementation of maintenance regimens, 6 -8 the incidence of end-stage renal disease in sle is increasing in the usa, 9 ,10 especially in african-american and Hispanic patients. Barriers to performing informative clinical trials of new drugs for lupus nephritis remain formid able. Disease heterogeneity, the con founding effects of other immunosuppressive medica tions and concurrent medical problems contribute to these difficulties. the past decade has witnessed an exciting increase in our understanding of the immunopathogenesis of autoimmunity. Despite many new discoveries, the path to the approval of any new therapy for sle is strewn with a growing list of failures, even for drugs that are effective in other diseases. Because some disease mechanisms are shared between humans and mice, the study of diverse mouse models has enabled acquisition of preclinical data that support clinical trials of novel therapies (table 1) . 11 the major disadvantages of relying on murine models are differences in physiology between mouse and man and the extensive genetic heterogeneity in an outbred human population, both of which complicate predictions of treatment efficacy. nevertheless, mechanistic studies of therapeutic interventions in murine lupus might help explain the difficulties encountered in identifying new drugs for human sle.
Pathogenesis of lupus nephritis
lupus nephritis is initiated by the glomerular deposition of immune complexes which triggers a cascade of inflammatory events including activation of Fc receptors 12 and complement, 13 recruitment of inflammatory cells and eventual fibrosis. immune complexes also activate resident renal cells through toll-like receptors (tlrs) to produce inflammatory mediators.
14 secondary lymphoid tissue has been reported in the renal parenchyma in some patients. 15, 16 interstitial nephritis occurs in the complete absence of circulating immunoglobulins in one murine lupus model; 17 similarly, pauci-immune nephritis has been observed in humans. 18 renal microvascular damage and thromboses also occur, especially in patients with anti-phospholipid antibodies. 19 several renal cell types including endothelial cells, podo cytes, interstitial cells and renal dendritic cells (DCs) are the focus of new studies in nephritis (Figure 1) . 20 renal migration of inflammatory cells requires endo thelial cell activation. 21 Hypoxia, owing to loss of glo merular and peritubular capillaries contributes to cell stress and cell death and induces molecules that further activate innate immune receptors. 22 molecules that protect the endothelium from hypoxia, such as oxygen sensors that regulate endothelial leak and micro thrombus formation 23 and receptors that regulate endothelial adhesive ness, are of growing interest. Patients with active sle have increased levels of angiopoietin-2, an antagonist of the tie2 receptor, which maintains endothelial inte grity and prevents leukocy te recruitment to the kidney; angiopoietin-2 www.nature.com/nrrheum might be a more-specific marker of renal involvement than soluble vascular cell adhesion molecule 1.
24 signals delivered via the vagus nerve to nicotinic acetylcholine receptors might exert a renoprotective effect by decreasing the levels of inflammatory cytokines and preserving endothelial integrity. 25 all these pathways are potential therapeutic targets for lupus nephritis. in addition, circulating endothelial cells 26 and endothelial protein C receptor 27, 28 are potential biomarkers of endothelial dy sfunction and damage.
the role of podocytes in renal inflammation is increasingly recognized, and their loss in chronic disease causes glomerulosclerosis. 29 Podocytes form a critical barrier to proteinuria and protect the endothelium by producing both glomerular basement membrane and vascular endothelial growth factor. 30 activation of angiotensin receptors on podocytes induces the release of inflammatory mediators and cell death; 31 blockade of angiotensin receptors protects podocytes and might be beneficial for lupus nephritis. 32 interstitial cell infiltration, tubular atrophy that follows vascular compromise, activation of smooth-muscle myofibroblast cells and interstitial fibrosis are all predictors of poor prognosis and/or progression to end-stage renal disease in lupus nephritis. 33, 34 activation of intrinsic renal DCs occurs in both murine lupus and human sle 21, 35 and is associated with an increased expression of inflam matory cytokines, proteolysis, and caspase-1 activity 21, 36 and upregulation of cell-surface molecules including CD11b. 21 Genetic differences involving both immune and nonimmune genes might influence the long-term outcome of renal inflammation although as yet no rigorous studies in lupus nephritis have been performed; these studies are challenging to perform even in the setting of renal transplant in which many more patients are available. 37 identification of polymorphisms in genes that enhance or protect from lupus nephritis such as ITGAM (which encodes the α chain of CD11b), 38 IL18 39 and kalli krein genes 40 suggest new avenues for investigation. Further studies of the mechanisms involved in intrinsic (Figure 2) .
B-cell-directed therapies B cells are culprits in autoimmunity not only as pro ducers of pathogenenic autoantibodies but also because they have diverse effector functions including antigen uptake and transport, 41 antigen presentation to t cells, 42, 43 production of cytokines 44 and chemokines, 45 and migration to sites of inflammation where they participate in further recruitment of inflammatory cells. 46, 47 in mice, B-cell deficiency completely prevents sle, whereas the complete absence of soluble antibodies only attenuates disease. 17 in humans, active sle is associated with high numbers of circulating autoreactive plasmablasts and plasma cells, expansion of memory B cells and a dearth of naive B cells. the plasma cells seen in active sle are in all probability newly generated as they are responsive to cyclophosphamide (indicating that they are still dividing) 48 or anti-CD40 ligand (which dissolves germinal centers). 49 although B-cell depletion seems an intuitive means to induce remission of sle, two recent trials of rituximab, an anti-CD20 antibody that depletes all B cells except plasma cells, have failed.
50,51 although anti-CD20 therapy depletes memory B cells and expands transitional B cells in some patients, other patients relapse with expanding populations of memory B cells. 52 anecdotal reports have suggested that cyclophosphamide-corticosteroidanti-CD20 antibody combination therapy induces remission of sle, including nephritis. However, in a trial in which nephritis patients received background mycophenolic acid and steroids with or without two courses of rituxi mab, no benefit of rituximab was observed at 52 weeks. moreover, an increase in B-cell activating factor (BaFF, also known as Blys or tumor necrosis factor ligand superfamily, member 13b) during the reconstitution phase might expand naive autoreactive or memory B cells. 53 anti-CD20 therapy is effective for both rheuma toid arthritis and multiple sclerosis, both of which are associated with the presence of effector B cells in target organs but with lower levels of systemic inflammation than occurs in sle. mouse studies have indicated that secondary lymphoid tissues in sle-prone mice are resistant to B-cell depletion even when depletion occurs in the peripheral blood. 54 whether more-aggressive therapy with anti-CD20 antibody, the use of concomitant cyclophosphamide, or BaFF blockade during B-cell reconstitution will be beneficial in human sle is still a matter of debate. reviews modulation of B-cell selection and survival can also be achieved by inhibition of BaFF and its homolog, a proliferation-inducing ligand (aPril; also known as tumor necrosis factor ligand superfamily, member 13). BaFF blockade does not prevent the formation of germinal centers 55 but results in partial B-cell depletion and more stringent selection of the naive autoreactive repertoire. 56 although memory B cells are BaFF-independent in normal mice, 57 BaFF boosts reactivation of memory B cells when inflammatory cytokines are present. 58 Depletion of plasma cells requires blockade of both BaFF and aPril; igm-producing plasma cells are more sensitive to this blockade than igG-producing ones, 59 probably because plasma cells in bone marrow niches receive alternative survival signals, especially during inflammation. intriguingly, activated macrophages and DCs express BaFF re ceptors; in mice, BaFF blockade prevents ac tivation of DCs in inflammatory sites, which results in local decreases in the release of interleukin (il)-6, ma turation of type 17 t-helper cells and plasma-cell survival. 60 BaFF blockade attenuates murine lupus-especially when administered before disease onset-but with consider able heterogeneity between models; 61 furthermore, in most models, blockade of BaFF alone is as effective as blockade of both BaFF and aPril, indicating that plasma-cell depletion is not required for this beneficial outcome. in some mouse strains the combination of a BaFF inhibitor and Ctla4-ig, an antagonist of B7-CD28 co-stimulation, induces remission of nephritis more effectively than either drug alone. Complete absence of BaFF does not prevent eventual glomerular damage and proteinuria in a model of spontaneous sle but does prevent renal failure and death, 62 perhaps because of a decreased inflammatory load. this observation suggests that careful 82 Agents with status listed as "planned" might not be listed on the clinical trials website as these studies are still in the development stage. Abbreviations: APRIL, a proliferation ligand (also known as tumor necrosis factor ligand superfamily, member 13); BAFF, B cell activating factor (also known as BLyS and as tumor necrosis factor ligand superfamily, member 13b); CD40L, CD40 ligand; ICOS, inducible T-cell co-stimulator; IFN, interferon; IL, interleukin; mTOR, mammalian target of rapamycin; SLe, systemic lupus erythematosus; TACI, tumor necrosis factor receptor superfamily, member 13b; TLR, Toll-like receptor; TNF, tumor necrosis factor; TNFR2, type 2 tumor necrosis factor receptor.
reviews analysis of short-term and long-term outcomes needs to be performed in clinical trials using B-cell depletion for the treatment of lupus nephritis. a fully humanized monoclonal anti-Blys/BaFF antibody (belimumab), which acts as a selective inhibitor of BaFF, has been evaluated in a phase ii study of generalized sle. although the trial failed to meet its primary endpoint, post-hoc analyses using a composite disease activity measure showed clinical efficacy in a subset of patients. 63 Preliminary results from a phase iii study in non-renal sle have shown that patients receiving belimumab plus standard care have an improved clinical response, including prevention of flares, compared with patients receiving placebo plus standard care over 52 weeks. 64 Patients who received belimumab demonstrated depleted peripheral naive and transitional B cells within 3-6 months with minimal effects on memory B cells and plasmablasts; autoantibody levels were only modestly affected but a small subset of patients became seronegative over a long period of time. whether belimumab has an effect on B-cell selection over time or whether chronic B-cell depletion will induce homeostatic expansion of auto reactive memory B cells remain to be determined. these findings confirm the mechanisms identified in mouse studies: explanations for the beneficial effects of BaFF blockade include the secondary effect of B-cell depletion on the expansion of other inflammatory cell populations and/or the inhibitory effect of BaFF blockade on immature DCs. whereas administration of taCi-ig, an agent that blocks both BaFF and aPril, might lead to consistent depletion of plasma cells, preferen tial depletion of igm-secreting plasma cells that produce protective antibodies 65, 66 could result in unacceptable toxic adverse effects.
t-cell-directed therapies
Ctla4-ig is beneficial in murine lupus, especially when given before class-switched and somatically mutated autoantibodies arise. 67 ,68 the follicular t-helper (t FH ) cells that drive B-cell help in germinal centers are completely dependent on CD28 co-stimulation. 69 However, tlrmediated signals together with various cyto kines including BaFF, il-21 and il-17 can substitute for B7-CD28 co-stimulation and drive reactivation of memory B cells. 58, 70 thus, administration of Ctla4-ig might be futile in active sle or chronic disease with persistent memory t cells and long-lived B cells. this alternative t-cell activation pathway might account for the failure of monthly Ctla4-ig (abatacept) treatment, coadministered with tapering doses of steroids, to alter autoantibody titers or rates of flare at 1 year in patients with non-renal flares. these studies confirm the challenges of using Ctla4-ig as a monotherapy in established disease. a study of abatacept in lupus nephritis is in progress. remission of active lupus nephritis can be achieved in mice using a combination of cy clophosphamide and Ctla4-ig. activated t cells and B cells are depleted by t FH cells might be targeted with il-17, il-21, CD40 and inducible t-cell co-stimulator antagonists, some of which are in early-stage human clinical trials. whereas il-21 is required for disease onset in some murine models, 71 it is dispensable in others, even when t FH cells are involved, 72 and its inhibition has only modest effects in late disease. anti-CD40 ligand therapy effectively prevents murine lupus but has less value for treating established nephritis. 73 thus, although t FH cells are required for disease initiation, either they are not sufficient for disease perpetuation or their inhibition in late disease requires blocking more than one molecule. whether targeting t FH cells is a viable therapeutic option remains to be determined. the role of regulatory t (t reG ) cells in lupus nephritis is still controversial. initial studies in murine models of spontaneous lupus have shown expansion of t reG cell subsets in the periphery and in the kidney over time 74 and adoptive transfer of large numbers of CD4 + CD25 + t reG cells in nZB × nZw lupus-prone mice had only a very modest effect on disease onset and survival. 75 this lack of effect may have arisen because t reG cells can be inactivated or can convert to type 17 t-helper cells in an inflammatory environment. 76 By contrast, induction of t reG cells by nondepleting anti-CD3 antibodies had very robust effects in snF 1 lupus-prone mice; in this case, suppression was mediated by inducible CD4
-t reG cells. 77 intriguing new data suggest that partial inhibition of the mammalian target of rapamycin (mtor) pathway might induce the expansion of t reG cells, 78 which points to an additional mechanism for the efficacy of mtor inhibitors in murine models of sle. Clearly much remains to be learned about the potential therapeutic role(s) of different types of t reG cells in sle.
several peptide-based strategies have induced robust therapeutic effects in murine models of lupus by inducing expansion of CD8 + t reG cells. [79] [80] [81] However, an initial phase ii trial of such an agent failed to meet its primary endpoint 82 and it remains to be determined whether this approach will be effective in humans.
targeting the innate immune system many patients with sle manifest a type i interferon (iFn) signature in the peripheral blood, induced by exposure of peripheral blood mononuclear cells to iFn-α and/or immune complexes. 83 type i iFns can induce either antiDna or anti-sm/rnP antibodies and accelerate disease in murine lupus by activating antigen-presenting cells, increasing the expression of tlrs and BaFF receptors, enhancing germinal-center formation and inducing the release of BaFF and il-6.
83,84 iFn-α blockers can inhibit iFn-α-accelerated disease 85 but whether iFns drive disease after the onset of inflammation remains unknown. Clinical trials of anti-iFn-α antibodies in sle are underway. in mice, increased levels of type i iFns confer relative resistance to both Ctla4-ig and inhibitors of BaFF (Z. liu and a. Davidson, unpublished work). this finding has two important implications. First, high serum levels of BaFF or t-cell-derived cytokines do not necessarily indicate sensitivity to inhibition of those cytokines. second, it might be necessary to randomize patients on the basis of their iFn signature in order to analyze the effects of other immune modulators.
whereas sle has classically been considered a t-cellmediated disease, initiation of lupus in mice transgenic for BaFF depends only on signaling through the myeloid differen tiation factor 88 (myD88), a tlr adaptor molecule. 86 intracellular tlrs can be targeted using short synthetic oligodeoxynucleotides. these oligodeoxynucleotides are more effective for preventing disease than for inducing remission in mice, and inhibitors of tlr7 are as effective as inhibitors of both tlr7 and tlr9. 87 the precise role for specific tlr inhibitors will IgG autoantibodies that recognize nucleic acids are internalized via FcR or BCR into TLR-expressing DCs or B cells respectively. TLR engagement in pDCs amplifies the production of type I IFN, 92 whereas TLR engagement in B cells increases BCR signaling and antibody production. 93 Therefore, once long-lived plasma cells that secrete autoreactive IgG are present, perpetuation of the autoreactive response might continue in a T-cell-independent manner (loop 2). During clinical disease, activated effector cells in inflamed organs produce cytokines that synergize with BAFF to enhance class switching and reactivation of memory B cells, and that directly cause tissue damage (loop 3). 58, 70 Memory B cells activate naive T cells, which results in epitope spreading; memory T cells and B cells might then interact in a co-stimulation-independent manner (loop 4). The multiple interacting and selfamplifying pathways that arise as SLe progresses make it difficult to induce remission of disease with a single immune-modulating agent. Abbreviations: BAFF, B-cell activating factor; BCR, B-cell antigen receptor; CD40L, CD40 ligand; FcR, Fc receptor; ICOS, inducible T-cell co-stimulator; IFN, interferon; IL, interleukin; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell; SLe, systemic lupus erythematosus; TLR, Toll-like receptor. reviews need to be addressed in human clinical trials. selective tlr9 inhibition might not be an appropriate strategy for treating sle because it could increase iFn-α production by immature DCs and thereby induce B cells to secrete pathogenetic anti-rna antibodies. 88 moreover, humans express a functional tlr8 in monocytes and myeloid DCs 89 and whether this tlr is blocked by available oligodeoxy nucleotides is unclear. nevertheless, the disease-modifying effects of hydroxychloroquine, an inhibitor of autophagosome formation (in which tlrs encounter nucleic acid antigens), 90 suggest that such agents might be beneficial.
Conclusions
Despite advances in our understanding of lupus pathogenesis we have not yet identified an effective new therapy for lupus nephritis. a number of clear themes are emerging from murine studies that bear upon this difficulty. First, mouse models are heterogeneous in their responses to therapies. in particular, mice with excessive activation of the innate immune system are resistant to t-cell-directed therapies. second, depletion of circulating autoantibodies does not always translate into an immediate clinical effect and, conversely, if antibody effector functions are blunted it is not essential to remove autoantibodies in order to improve nephritis outcomes. third, therapies that deplete naive B cells do not have robust efficacy in active disease and could lead to expansion of autoreactive B cells in the face of general ized immunosuppression. Fourth, whereas many therapies prevent disease onset, most have substantially compromised efficacy when used at later stages. For established disease, combined therapy is more effective than monotherapy, but is considerably more immunosuppressive. Because the inflammatory milieu of chronic sle profoundly alters t-cell and B-cell functions and establishes dysregulated amplification loops, restoration of normal tolerance is difficult to achieve once the disease has begun. some of these changes might persist, as they are associated with the genera tion of long-lived populations of effector cells and with alterations in Dna methylation. 91 Finally, genetic polymorphisms that alter the susceptibility of the kidneys to inflammation and fibrosis will affect prognosis.
Data from murine models of lupus suggest that we need to reconsider current paradigms for the management of sle. at present, we reserve immunologic interventions for patients with active disease and withdraw medications from patients with inactive disease. the most logical strategy is to prevent activation of auto reactive cells before the occurrence of class-switching and somatic mutation of immunoglobulin genes, the formation of long-lived popula tions of autoreactive cells, and the establishment of multiple dysregulated inflammatory pathways. approaches to treating newly diagnosed sle after remission of the first flare could include relatively safe forms of long-term immune modulation, as well as some of the agents discussed above. several agents (such as vitamin D, 'natural' igm, inhibitors of angiotensin-converting enzyme, cholinergic agonists, statins, N-acetylcysteine and PPar agonists) might confer protection without suppressing the immune system; clinical trials for these agents are ongoing. Comorbidities such as hypertension and obesity need to be treated aggressively in the early stages of sle. in addition, genetic and phenotypic profiling might enable identification of subgroups of patients more likely to respond to particular therapies. once inflammation is present, intensive immunotherapy can deplete activated B cells and t cells but strategies to avoid reconstitution of an autoreactive repertoire and/or homeostatic proliferation of long-lived populations of these cells are needed. therapies directed at effector pathways should be developed and used early during the disease course to protect target organs from damage. Both short-term and long-term outcomes must be examined in clinical trials. the success of belimumab, an agent directed at both autoreactive B cells and target organs, exem plifies the principle that measuring the results of moderate immune modulation for the maintenance of long-term remission requires large and prolonged clinical trials of agents that target more than one immune pathway.
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